Status:
COMPLETED
A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine if a flexible dose of Symbicort has a similar effect on the airways of patients with asthma as a higher fixed-dose of Symbicort with additional glucocorticost...
Eligibility Criteria
Inclusion
- Diagnosis of asthma for at least 6 months
- Prescribed daily use of glucocorticosteroids for at least 3 months prior to visit one
Exclusion
- Respiratory infection affecting asthma within 30 days prior to study
- Intake of oral, rectal, or parenteral glucocorticosteroids within 30 days prior to study
- Any significant disease or disorder that may jeopardize the safety of the patient
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
End Date :
March 1 2007
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00244608
Start Date
May 1 2005
End Date
March 1 2007
Last Update
January 24 2011
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aalborg, Denmark
2
Research Site
Århus C, Denmark
3
Research Site
Copenhagen, Denmark
4
Research Site
Montpellier, France